CN109666741A - A kind of application of new gastric cancer marker gene circPTPDC1 - Google Patents
A kind of application of new gastric cancer marker gene circPTPDC1 Download PDFInfo
- Publication number
- CN109666741A CN109666741A CN201910094141.7A CN201910094141A CN109666741A CN 109666741 A CN109666741 A CN 109666741A CN 201910094141 A CN201910094141 A CN 201910094141A CN 109666741 A CN109666741 A CN 109666741A
- Authority
- CN
- China
- Prior art keywords
- circptpdc1
- seq
- gastric cancer
- pcr
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses the applications of new gastric cancer marker gene circPTPDC1 a kind of, are related to the discovery, detection, application of circPTPDC1 molecular marker, design and synthesize out the detection primer for being specifically used for real-time quantitative PCR.It is poor to gastric cancer Endoscopic Screening compliance for target group, and the patients with gastric cancer overwhelming majority clinically made a definite diagnosis is the status proposition of middle and advanced stage, ideal molecule pre-warning signal is found in gastric cancer canceration process, targetedly carry out endoscopy, definitive pathological diagnosis, to mitigate patient's pain, over-treatment is avoided, medical resource is saved.Present invention discover that blood circPTPDC1 can be used as patients with gastric cancer lymphatic metastasis and monitor the marker of prognosis.
Description
Technical field
The present invention relates to oncomolecularbiology fields, and a kind of specially new gastric cancer marker gene circPTPDC1's answers
With.
Background technique
Currently, gastric cancer is still number three position in global cancer related mortality, it is one of major health burden of society.?
China, gastric cancer are second to be very popular cancer, and lead to the second largest reason of cancer mortality, and it is new to be estimated to be within 2015 679,100
Case and 498,000 people are dead.Although surgical technic and Combination chemotherapy are improved, in most countries, the 5 of gastric cancer
Year, total existence was still below 30%, in default of early gastric caacer diagnosis marker.Therefore, it is necessary to carefully explore gastric cancer relevant molecule
Feature, and develop reasonable early gastric caacer detection method.
Circular rna (circRNA) is considered as being generated by the non-classical montage of linear precursor mRNA, is infected in virus-like
Property particle such as viroid, round satellite virus and Hepatitis D virus found extensively.Circular rna s seemingly wrong RNA is cut
It is connecing as a result, do not find its key effect and function always, find recently and for good and all change us
To the viewpoint of cancer, especially canceration and cancer progression.So far, it has discovered that in mammalian cells some endogenous
Property circRNA, and they in tumour progression can with high abundance exist and evolutionary conservatism.In addition, having had a large amount of
Research confirms that circular rna can be adjustable transcription and manipulate the access of microRNA.Having several circRNA is considered as causing cancer thin
The reason of born of the same parents' malignant behaviors.However, many can be used as since we are limited the understanding of circRNA
The circRNA that microRNA works may be found not yet.More and more evidences show that circRNA may include
It plays an important role in the occurrence and development of cancer including gastric cancer, and is likely to become the newborn marker of cancer.Zhang J's
Team discovery circLARP4 is lowered in stomach organization, and is inhibited by amplification miR-424 targeting in LATS1 gene
The biological behaviour of stomach cancer cell, this is the independent prognostic factor that patients with gastric cancer is always survived.
Currently, in the prior art, crossing the Tumor invasions such as CEA/CA199/CA153 in detection blood samples of patients all and suffering to assess
The state of an illness of person, these index specificity and sensitivity are poor.
Summary of the invention
To solve the above problems, the invention discloses the application of new gastric cancer marker gene circPTPDC1 a kind of, for
Target group is poor to gastric cancer Endoscopic Screening compliance, and the patients with gastric cancer overwhelming majority clinically made a definite diagnosis is showing for middle and advanced stage
Shape proposes, ideal molecule pre-warning signal is found in gastric cancer canceration process, targetedly carries out endoscopy, pathology is true
It examines, to mitigate patient's pain, avoids over-treatment, save medical resource.Present invention discover that blood circPTPDC1 can be used as gastric cancer
The marker of patient's lymphatic metastasis and monitoring prognosis.
In order to reach the goals above, the present invention supplies following technical solution:
The invention discloses the application of new gastric cancer marker gene circPTPDC1 a kind of, the nucleosides of the circPTPDC1
Acid sequence is SEQ ID NO.1, marker of the circPTPDC1 as diagnosing gastric cancer and prognosis.
It in the present invention, is real-time quantitative PCR kit for the reagent of diagnosing gastric cancer.
In the present invention, 2 pairs of primers are devised for examining according to the circPTPDC1 that nucleotides sequence is classified as SEQ ID NO.1
The sequence is surveyed, primer nucleotide sequences are SEQ ID NO.2, shown in SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5.
Use GAPDH as internal contrast, GAPDH (F), 5'-GCATCCTGGGCTACACTG-3', nucleotides sequence is classified as
SEQ ID NO.2；GAPDH (R), 5'-ACTTCAGGAGCATCTGAAATAGGT-3', nucleotides sequence are classified as SEQ ID NO.3.
Using primer pair, upstream primer: 5 '-CTTTCATGGAGGCTGGCATT-3 ', nucleotides sequence are classified as SEQ ID
NO.4.Downstream primer, 5 '-TGCAGCCATGGTAGTCTGTT-3 ' nucleotides sequence are classified as SEQ ID NO.5.
The invention also discloses the detection methods of circPTPDC1, extraction, reverse transcription and real-time quantitative PCR including RNA.
Specifically: total serum IgE in tissue is extracted by using TRIzol reagent, and is extracted by TIANamp Virus RNA kit
Total serum IgE in blood plasma；Using Prime-Script by RNA reverse transcription at cDNA TM One step RT-PCR kit, glyceraldehyde 3-
Phosphate dehydrogenase (GAPDH) is used as internal contrast；Use following primer pair: 5 '-CTTTCATGGAGGCTGGCATT-3 '
(Forward, or F) and 5 '-TGCAGCCATGGTAGTCTGTT-3 ' (reverse, R), it is determined by qRT-PCR
CircPTPDC1 expression；Use GAPDH as internal contrast, uses primer pair 5'-GCATCCTGGGCTACACTG-3'
(F) and 5'-ACTTCAGGAGCATCTGAAATAGGT-3'(R).Use ABI7500 system and SYBR Green PCR Master
Mix carries out all qRT-PCR reactions.For the multiple variation of circPTPDC1 expression in accurate validation GC tissue, by calculating
Ct value is standardized relative to the GAPDH (Δ Ct=Cttested-CtGAPDH) expanded from same sample, and use-Δ side Ct
Method come estimate variation value.In triplicate, all reactions are independent in triplicate to ensure weighing for all data for each sample
Renaturation.The Cutoff value of circPTPDC1 is -12.55, when what is detected-Δ Ct is gastric cancer, specificity when being greater than this value
It is 66.67%, sensibility 69.44%.
The invention also discloses a kind of real time quantitative PCR detecting reagent kits for diagnosing gastric cancer, including according to nucleotide
Sequence is that the circPTPDC1 molecular marker of SEQ ID NO.1 designs and synthesizes out the inspection for being specifically used for real-time quantitative PCR
Survey primer.
In the present invention, further, the specific primer includes upstream primer and SEQ shown in SEQ ID NO.4
Downstream primer shown in ID NO.5.
The invention also discloses a kind of molecular marker for diagnosing gastric cancer, the molecular marker is nucleotide sequence
For the circPTPDC1 molecular marker of SEQ ID NO.1.
For detecting the specific primer of circPTPDC1 molecular marker, the specific primer includes SEQ ID
Downstream primer shown in upstream primer shown in NO.4 and SEQ ID NO.5.
The present invention has the advantage that
(1) purposes of circPTPDC1 is proposed.(2) circular rna has mechanism stable, abundance degree and tissue specificity table
Up to etc. features.And circPTPDC1 has differences in gastric cancer and expression quantity in cancer beside organism, and to it is by stages related, therefore
CircPTPDC1 has the application prospect as gastric cancer biomarker.
The present invention be directed to target group is poor to gastric cancer Endoscopic Screening compliance, and the patients with gastric cancer clinically made a definite diagnosis is exhausted
Most of is all that the status of middle and advanced stage proposes, it would be desirable to find ideal molecule pre-warning signal in gastric cancer canceration process, there is needle
To the carry out endoscopy of property, definitive pathological diagnosis avoids over-treatment, saves medical resource to mitigate patient's pain.This patent hair
Existing blood circPTPDC1 can be used as the marker of patients with gastric cancer diagnosis.
Detailed description of the invention
Fig. 1, display circPTPDC1 derive from PTPDC1 exon 2-6；
Fig. 2, with the qRT-PCR of the abundance of circPTPDC1 and PTPDC1mRNA in the GC cell of RNase R processing；
The significant expression higher than the adjacent non-cancer tissue of GC patient of expression of Fig. 3, circPTPDC1 expression；
Fig. 4, ROC curve；
The up-regulation of Fig. 5, circPTPDC1 level is positively correlated with TNM stage；
The expression of the expression of Fig. 6, circPTPDC1 in GC blood samples of patients is significant to be higher than normal person.
In figure: P < 0.01 * P < 0.05, * *.
Specific embodiment
With reference to the accompanying drawings and detailed description, the present invention is furture elucidated, it should be understood that following specific embodiments are only
For illustrating the present invention rather than limiting the scope of the invention.
The invention discloses the application of new gastric cancer marker gene circPTPDC1 a kind of, circPTPDC1 molecular markers
Nucleotides sequence be classified as SEQ ID NO.1, marker of the circPTPDC1 as diagnosing gastric cancer and prognosis.Experiment side below
Method is specific embodiment, and experimental result is as shown in Figures 1 to 5.
Experimental procedure:
The sequencing of 1.RNA mulberry lattice
(1) amplified production insertion is used in the T- carrier of mulberry lattice (Sanger) sequencing determine their overall length.Design
Different primers is to confirm that circPTPDC1's returns splice junction.Primer is synthesized by Invitrogen company (Chinese Shanghai), Sang Ge
Sequencing is completed by the Realgene company of Nanjing of China.
2.RNase R digestion
2mg total serum IgE is incubated 20 minutes at 37 DEG C, is added or is added without 3U/mg RNase R, then uses RNeasy
MinElute kit.
3. patient and case screening
It is collected into 36 GC tissues altogether from GC patient and corresponding adjacent non-tumor tissue sample, all tissue samples is equal
From department of general surgery, attached Nanjing hospital, Nanjing Medical University (in January, 2013 is to during in December, 2017).All patients in group exist
Preoperative row radiation and chemotherapy, and their tissue samples are stored in immediately in RNA fixating reagent, and be immediately placed in -80 DEG C
It is saved in refrigerator.The adjacent nonneoplastic tissue of pairing need to not have tumour cell by pathological analysis, and be located in apart from knurl
At edge 5cm.According to tumour-lymphatic metastasis (TNM) Staging System of International Union Against Cancer, all tumours it is accurate by stages.
Every patient signs Written informed consent, and the local medical ethics committee has approved the research approach.
GC cancer patient's blood sample 21 in this research, normal human blood sample 17.
4. clinical tissue sample samples
(1) preparatory items:
Liquid nitrogen container (checking liquid nitrogen volume, fill liquid nitrogen in time in advance), ice chest, ice physiological saline, sterile no enzyme cryopreservation tube
(dispensed RNA protection liquid and numbered spare), sterile glove (without talcum powder), mask, cap, tweezers, scissors, low temperature mark
Pen etc..
(2) operating process:
A. determine and left and taken its blood sample patient is preoperative, and extract flow processing according to blood sample, after will extract
Serum move into Greiner cryopreservation tube in and with red low temperature marking pen marker number, be stored in low temperature refrigerator, and be recorded in disease
In example data sheet and its electronic version.
B. it is pre-filled with tissue specimen case-data table (recording effective contact method in order to follow-up), pays attention to filling in interior
The integrality of appearance.The number for leaving and taking the cryopreservation tube of cancer and cancer beside organism is predefined, and is numbered and is recorded in case-data table
In.
C. be immediately placed in kidney basin after tissue is in vitro, rapidly with brine ice shower (low temperature can temporarily inhibit RNA enzyme activity with
Strive for sample time；The blood mixed in washing tissue samples, reduces pollution；Maintain the permeability of tissue samples in favor of RNA
Protection liquid permeates rapidly and plays Inhibitory activity).
D. it chooses mucosa tissue and is broken down into the fritter packing of about soya bean size, pay attention to sampling sequence: taking 2~4
Block Carcinoma side normal tissue and 2~4 pieces of tumor tissues, thickness are no more than 5mm, first take normal tissue, then take tumor tissues, a jelly
Depositing pipe only is suitable for one piece of sample of storage, and the cryopreservation tube for not obscuring tumour and peri- tumorous normal tissues is numbered.
E. cryopreservation tube is tightened after the completion of sampling (to penetrate into cryopreservation tube as do not screwed bottle cap liquid nitrogen, take out and freeze under normal temperature state
Deposit Guan Shiyi initiation freeze pipe explosion), be softly inverted and rock cryopreservation tube, make tissue and protection liquid mix, after be immediately placed in liquid
In nitrogen tank.
F. whether inspection tissue specimen case-data table is filled in perfect, predefines and records in " refrigerator sample positions table "
Enter storage location of the sample in profound hypothermia refrigerator, the sample in liquid nitrogen container is moved into profound hypothermia refrigerator in time.It avoids because of carelessness
Forget, causes sample waste after liquid nitrogen volatilization totally unavailable.
G. postoperative one week tracking pathological replacement determines whether sample can enter as a result, simultaneously in timely typing case-data table
Group research.
Extraction, reverse transcription and the real-time quantitative PCR of 5.RNA
Total serum IgE in tissue is extracted by using TRIzol reagent, and is extracted by TIANamp Virus RNA kit
Total serum IgE in blood plasma.Using Prime-Script by RNA reverse transcription at cDNA TM One step RT-PCR kit, glyceraldehyde 3-
Phosphate dehydrogenase (GAPDH) is used as internal contrast.Use following primer pair: 5 '-CTTTCATGGAGGCTGGCATT-3 '
5 '-TGCAGCCATGGTAGTCTGTT-3 ' (reverse, R) of (Forward, or F) and is determined by qRT-PCR
CircPTPDC1 expression.Use GAPDH as internal contrast, uses primer pair 5'-GCATCCTGGGCTACACTG-3'
(F) and 5'-ACTTCAGGAGCATCTGAAATAGGT-3'(R).Use ABI7500 system and SYBR Green PCR Master
Mix carries out all qRT-PCR reactions.For the multiple variation of circPTPDC1 expression in accurate validation GC tissue, by calculating
Ct value is standardized relative to the GAPDH (Δ Ct=Cttested-CtGAPDH) expanded from same sample, and use-Δ side Ct
Method come estimate variation value.In triplicate, all reactions are independent in triplicate to ensure weighing for all data for each sample
Renaturation.The Cutoff value of circPTPDC1 is -12.55, when detect-Δ Ct be greater than this value when for gastric cancer, specificity
It is 66.67%, sensibility 69.44%.
Laboratory operating procedures:
(1) Trizol extracts tissue RNA:
A. it wears masks and gloves, opens 4 DEG C of refrigerated centrifuges, it is spare to set temperature.The sample number extracted needed for calculating,
The sterile no enzyme EP pipe of 1.5ml for preparing double quantity, is placed in spare on EP pipe support.
B. it grinds in vessel and pours into appropriate Liquid nitrogen precooler, take in 50-100mg tissue merging liquid nitrogen, tissue abrasion to powder
Shape.
C. 1ml Trizol is added into grinding vessel, continues the mixture of the tissue and Trizol of grinding solidification shape.
D. it stands to its liquefaction, is transferred in Rnase free 1.5ml EP pipe.
E. 5min is stood at room temperature, and 200ul chloroform is added in every 1ml Trizol.
F. 15s is acutely shaken, stands 2-3min at room temperature.
G.4 DEG C, 12000g-14000g is centrifuged 15min.
H. for transfer water phase into new Rnase free 1.5ml EP, 500ul isopropanol, room is added in every 1ml Trizol
Temperature places 10min.
I.4 DEG C, 12000g is centrifuged 10min.75% ethyl alcohol (need to be prepared with DEPC water) of prewired cleaning RNA.
J. it carefully discards supernatant, at least 75% ethanol washing RNA precipitate of 1ml, vortex mixed is added in every pipe.
K.4 DEG C, 7500-10000g is centrifuged 5-10min.Carefully discard supernatant.
L. RNA precipitate (RNA is colourless after air-drying) is air-dried, (is added according to precipitating size using DEPC- water dissolution precipitating
10-80ul or so), with pipette tips suction beat blow it is even.
(2) Trizol extracts cell RNA:
A. cell to be extracted is cleaned twice with PBS.
B. appropriate Trizol (bottle/six orifice plates every hole 1ml, big ware 3ml, big bottle 5ml) into culture vessel is added.
C. it blows and beats several times, is transferred in Rnase free 1.5ml EP pipe repeatedly.
D. 5min is stood at room temperature, and 200ul chloroform is added in every 1ml Trizol.
E. 15s is acutely shaken, stands 2-3min at room temperature.
F.4 DEG C, 12000-14000g is centrifuged 15min.
G. for transfer water phase into new Rnase free 1.5ml EP, 500ul isopropanol, room is added in every 1ml Trizol
Temperature places 10min.
H.4 DEG C, 12000g is centrifuged 10min.
I. it discards supernatant, at least 75% ethanol washing RNA precipitate of 1ml, vortex mixed is added.
J.4 DEG C, 7500-10000g is centrifuged 5-10min.
K. RNA precipitate is air-dried, is used DEPC- water dissolution precipitating (10-80ul or so is added according to precipitating size).
(3) extracted sample rna concentration is detected:
A. it is (each to be detected each sample to be tested to be configured in new Rnase free200ul EP pipe according to 1% concentration
Sample 1ul+99ulDEPC water).
B. ultraviolet specrophotometer is opened, cuvette is cleaned, takes 100ulDEPC water that blank control is set.
C. it is implanted sequentially sample to be tested and detects and record concentration of specimens, OD260/280 ratio.
(4) RNA reverse transcription:
A. Reverse Transcriptase kit is taken out from -20 DEG C of refrigerators, by 2 kinds of enzyme insertion ice chest ice, other reagents melt on ice,
RNase Free water room temperature melts spare.
B. according to surveyed RNA concentration, RNA volume needed for calculating the every pipe of reverse transcription, and DEPC water volume is calculated simultaneously.
C. it takes PCR pipe to be placed on ice, be put into sterile no enzyme 200ul PCR pipe as needed and mark by number.Pipettor
After drawing appropriate RNA, pipette tips are inserted perpendicularly into PCR pipe bottom, at the uniform velocity softly get liquid.
D. pipettor draws appropriate DEPC water, and pipette tips are squeezed into PCR pipe close to rear wall.
E. reverse transcription Step1: gDNA Eraser 1ul and 5x gDNA Eraser Buffer 2ul is added in every pipe.
F. it is placed on eight union centrifuges, gently bullet falls tube bottom or tube wall bubble, is centrifuged in short-term.
42 DEG C 2 minutes on G.RT-PCR instrument, product is placed in spare on ice after reaction.
H. it reverse transcription Step2: takes 1.5ml EP to manage, according to formula as below, configures every tube reaction Mix
Setting reaction condition: 37 DEG C, 15min；85 DEG C, 5sec；4 DEG C of maintenances.
I. pipe lid is fastened, it is taken off from pipe support, is placed on centrifuge tube shelf, having bubble, person can flick tube bottom, in short-term
Centrifugation resets after confirming that the liquid of every pipe equals the interior bubble-free of consistent and pipe on ice.
J., reaction condition is set: 37 DEG C, 15min；85 DEG C, 5sec；4 DEG C of maintenances.Operate the computer, by cDNA after 15-20min
It is placed in -20 DEG C of preservations.
(5) qRT-PCR step:
A. ice chest is got out, cDNA, the primer, PCR reagent of sample to be tested are taken out from -20 DEG C of refrigerators, is thawed on ice.
B. the liquid relief of eight unions and Guan Gai, eight union framves, tweezers, sterile 1.5ml EP pipe, EP pipe support, suitable range is got ready
Device, aseptic thin-film gloves.
C. by the cDNA to have thawed, primer, PCR reagent, first successively oscillation is centrifuged in short-term, on ice stand for standby use.
D. according to detection sample and index quantity, different target gene sample application regions are divided.Eight unions are placed on ice,
Eight unions are clamped with tweezers and are laid down on eight union framves.
E. it takes 1.5ml EP to manage, prepares eight union PCR Mix by every hole 19ul below, and shake centrifugation.
F. by each sample and multiple holes are preset in the position of eight unions, the 1ul cDNA and 19ul of sample are sequentially added
PCR Mix。
G. bubble is removed in centrifugation, operates the computer, and reaction condition is arranged.
(6) qRT-PCR reaction system:
QRT-PCR reaction condition:
6, data are analyzed:
As shown in figures 1 to 6, Fig. 1, display circPTPDC1 derives from PTPDC1 exon 2-6 to experimental result.Amplification is produced
Overall length of the object insertion for determining them in the T- carrier of Sanger sequencing.Different primers is designed to confirm
CircPTPDC1:5'-AGGGCTTGGTCGAACAG-3'(ariyoshi) and 5'-ACTACCATGGCTGCAGG-3'(antisense) return cut
Contact；Fig. 2, with the qRT-PCR of the abundance of circPTPDC1 and PTPDC1mRNA in the GC cell of RNase R processing；Fig. 3,
The significant expression higher than the adjacent non-cancer tissue of GC patient of expression of circPTPDC1 expression.Determined they-Δ Ct value
Correlation；Fig. 4, ROC curve have been used for the assessment potential diagnostic value of circPTPDC1, and area (AUC) adds up under ROC curve
0.758.It is 0.809 that circPTPDC1, which expresses the expression AUC in GC advanced stage (IIIA-IV) the TNM phase, is higher than early stage (IA-IIB)
The TNM phase；The up-regulation of Fig. 5, circPTPDC1 level is positively correlated with TNM stage；Fig. 6, circPTPDC1 are in GC blood samples of patients
Expression expression it is significant be higher than normal person.In figure: P < 0.01 * P < 0.05, * *.
Examined using t and the method circPTPDC1 of Chi-square Test and survival analysis and patients with gastric cancer clinical stages data and
The correlation of prognosis.Receiver Operating Characteristics' (ROC) curve is carried out to assess its diagnostic value.All statistical analysis use
V.17.0, SPSS for Windows is carried out.For all as a result, P < 0.05 is considered statistically significant.
The technical means disclosed in the embodiments of the present invention is not limited only to technological means disclosed in above embodiment, further includes
Technical solution consisting of any combination of the above technical features.It should be pointed out that for those skilled in the art
For, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also considered as
Protection scope of the present invention.
Sequence table
<110>Jiangsu ten thousand is at Co., Ltd, biomedical research institute
<120>a kind of application of new gastric cancer marker gene circPTPDC1
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 200
<212> DNA
<213> Homo sapiens
<400> 1
gcgtctctta ctactatcct agatatggtg aaggtgatga catttgcctt acaggaagga 60
aaagtagcta tccattgtca tgcagggctt ggtcgaacag actaccatgg ctgcaggagt 120
cttgcctcag aatgaacaac catattctac cttggtgaat aacagcgagt gtgttgcaaa 180
catgaaagga aatttagaac 200
<210> 2
<211> 18
<212> DNA
<213> Homo sapiens
<400> 2
gcatcctggg ctacactg 18
<210> 3
<211> 24
<212> DNA
<213> Homo sapiens
<400> 3
acttcaggag catctgaaat aggt 24
<210> 4
<211> 20
<212> DNA
<213> Homo sapiens
<400> 4
ctttcatgga ggctggcatt 20
<210> 5
<211> 20
<212> DNA
<213> Homo sapiens
<400> 5
tgcagccatg gtagtctgtt 20
Claims (9)
1. a kind of application of new gastric cancer marker gene circPTPDC1, the nucleotides sequence of the circPTPDC1 are classified as SEQ ID
The marker of NO.1, the circPTPDC1 as diagnosis of gastric cancer by stages.
2. application as described in claim 1, it is characterised in that: the reagent for diagnosing gastric cancer is real-time quantitative PCR kit.
3. application as claimed in claim 1 or 2, it is characterised in that: be classified as SEQ ID NO.1's according to nucleotides sequence
It is SEQ ID NO.2, SEQ ID that circPTPDC1, which devises 2 pairs of primers for detecting the sequence, primer nucleotide sequences,
NO.3, SEQ ID NO.4, shown in SEQ ID NO.5.
4. application as described in claim 1, it is characterised in that: the detection method of circPTPDC1, it is extraction including RNA, anti-
Transcription and real-time quantitative PCR.
5. application as claimed in claim 4, it is characterised in that: the specific steps of detection method, comprising: by using TRIzol
Reagent extracts total serum IgE in tissue, and extracts the total serum IgE in blood plasma by TIANamp Virus RNA kit；It uses
For Prime-Script by RNA reverse transcription at cDNA TM One step RT-PCR kit, glyceraldehyde 3 phosphate dehydrogenase is used as inside
Control；Use following primer pair: shown in SEQ ID NO.4, SEQ ID NO.5；Determine that circPTPDC1 is expressed by qRT-PCR
It is horizontal；All qRT-PCR reactions are carried out using ABI7500 system and SYBR Green PCR Master Mix.
6. a kind of real time quantitative PCR detecting reagent kit for diagnosing gastric cancer, it is characterised in that: including being classified as according to nucleotides sequence
The circPTPDC1 molecular marker of SEQ ID NO.1, which designs and synthesizes out, to be specifically used for the detection of real-time quantitative PCR and draws
Object.
7. existing as claimed in claim 6 for diagnosing gastric cancer or the real time quantitative PCR detecting reagent kit of prognosis, feature
In: the specific primer includes downstream primer shown in upstream primer shown in SEQ ID NO.4 and SEQ ID NO.5.
8. a kind of molecular marker for diagnosing gastric cancer, which is characterized in that the molecular marker is that nucleotides sequence is classified as SEQ
The circPTPDC1 molecular marker of ID NO.1.
9. the specific primer for detecting molecular marker described in claim 1, which is characterized in that the specific primer packet
Include downstream primer shown in upstream primer shown in SEQ ID NO.4 and SEQ ID NO.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910094141.7A CN109666741B (en) | 2019-01-30 | 2019-01-30 | Application of novel gastric cancer marker gene circPTPDC1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910094141.7A CN109666741B (en) | 2019-01-30 | 2019-01-30 | Application of novel gastric cancer marker gene circPTPDC1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109666741A true CN109666741A (en) | 2019-04-23 |
| CN109666741B CN109666741B (en) | 2022-06-10 |
Family
ID=66150069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910094141.7A Active CN109666741B (en) | 2019-01-30 | 2019-01-30 | Application of novel gastric cancer marker gene circPTPDC1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109666741B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110894528A (en) * | 2019-09-22 | 2020-03-20 | 潘文胜 | CircRNA marker for diagnosing gastric poorly differentiated adenocarcinoma and application thereof |
| CN113604567A (en) * | 2021-07-29 | 2021-11-05 | 中国人民解放军总医院第一医学中心 | CircRNA molecular diagnosis group, use method and application thereof, kit and chip |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2503009A1 (en) * | 2011-03-25 | 2012-09-26 | Massimo Zollo | Biomarker for detecting circulating tumor cells and related detecting methods and kit |
| CN106434953A (en) * | 2016-10-27 | 2017-02-22 | 宁波大学 | Detection and application of novel molecular marker hsa-circ-0074362 for gastric cancer |
| CN106591428A (en) * | 2016-09-23 | 2017-04-26 | 宁波大学 | Detection and application of new molecular marker hsa-circ-0001017 of gastric cancer |
| CN106811525A (en) * | 2017-02-10 | 2017-06-09 | 南方医科大学南方医院 | A kind of kit and system for predicting the recurrence of III phase patients with gastric cancer early postoperation |
| CN107083432A (en) * | 2017-05-27 | 2017-08-22 | 邵永富 | A kind of stomach cancer molecular marker hsa_circ_0000705 and its application |
| CN107177669A (en) * | 2017-05-27 | 2017-09-19 | 叶国良 | A kind of stomach cancer molecular marker hsa_circ_0006633 and its application |
-
2019
- 2019-01-30 CN CN201910094141.7A patent/CN109666741B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2503009A1 (en) * | 2011-03-25 | 2012-09-26 | Massimo Zollo | Biomarker for detecting circulating tumor cells and related detecting methods and kit |
| CN106591428A (en) * | 2016-09-23 | 2017-04-26 | 宁波大学 | Detection and application of new molecular marker hsa-circ-0001017 of gastric cancer |
| CN106434953A (en) * | 2016-10-27 | 2017-02-22 | 宁波大学 | Detection and application of novel molecular marker hsa-circ-0074362 for gastric cancer |
| CN106811525A (en) * | 2017-02-10 | 2017-06-09 | 南方医科大学南方医院 | A kind of kit and system for predicting the recurrence of III phase patients with gastric cancer early postoperation |
| CN107083432A (en) * | 2017-05-27 | 2017-08-22 | 邵永富 | A kind of stomach cancer molecular marker hsa_circ_0000705 and its application |
| CN107177669A (en) * | 2017-05-27 | 2017-09-19 | 叶国良 | A kind of stomach cancer molecular marker hsa_circ_0006633 and its application |
Non-Patent Citations (3)
| Title |
|---|
| CIRCBASE: "has_circ0008577", 《CIRCBASE》 * |
| MEI HUANG等: "Circular RNA hsa_circ_0000745 may serve as a diagnostic marker for gastric cancer", 《WORLD JOURNAL OF GASTROENTEROLOGY》 * |
| 陈京燕等: "cir-ITCH在胃癌患者肿瘤组织中的表达及临床应用", 《临床检验杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110894528A (en) * | 2019-09-22 | 2020-03-20 | 潘文胜 | CircRNA marker for diagnosing gastric poorly differentiated adenocarcinoma and application thereof |
| CN113604567A (en) * | 2021-07-29 | 2021-11-05 | 中国人民解放军总医院第一医学中心 | CircRNA molecular diagnosis group, use method and application thereof, kit and chip |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109666741B (en) | 2022-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109890394A (en) | The Microrna of biomarker as endometriosis | |
| CN109988845B (en) | A kind of application of new stomach cancer marker circ-EIF4G3 | |
| ES2691404T3 (en) | Non-invasive cancer diagnosis | |
| CN105219867A (en) | For miRNA biomarker and the detection kit of diagnosing gastric cancer | |
| US20220228223A1 (en) | Squamous cell carcinoma diagnostic or prognosis prediction marker and use thereof | |
| CN110484624A (en) | A kind of gastric cancer biomarker and its detection method and application based on peripheral blood | |
| CN105177174A (en) | miRNA (microribonucleic acid) biomarkers and detection kit for colon cancer diagnosis | |
| CN106191055A (en) | A kind of non-small cell lung carcinoma marker, detectable and test kit | |
| CN105177173A (en) | miRNA (microribonucleic acid) biomarkers and detection kit for ovarian cancer diagnosis | |
| CN109666741A (en) | A kind of application of new gastric cancer marker gene circPTPDC1 | |
| CN112501294B (en) | Colorectal cancer biomarker and application thereof | |
| CN109593857A (en) | In blood circ-DLG1 molecular marker diagnosis esophageal squamous cell carcinoma by stages in application | |
| CN109666742A (en) | A kind of application of new gastric cancer marker gene circ-CC2D1A | |
| CN110257514A (en) | A kind of new cancer of the esophagus blood miRNA marker and its application | |
| CN105219841B (en) | A kind of detection kit and its application of lung cancer differential expression microRNA | |
| CN105441566A (en) | Kit for postoperative and prognosis evaluation of liver cancer and liver cancer chemosensitizer | |
| US20230265523A1 (en) | Molecular marker for early pancreatic neoplasm detection, detection method and use thereof | |
| CN106702015A (en) | Application of IPCEF1 (Interaction Protein For Cytohesin Exchange Factors 1) in diagnosing and treating osteosarcoma | |
| CN109234401B (en) | Molecular marker for diagnosing gastric adenocarcinoma | |
| CN106282366A (en) | A kind of molecular marked compound relevant to carcinoma of prostate and application thereof | |
| CN113637753A (en) | Bladder cancer marker lncRNA TERC based on urine exosome and application thereof | |
| WO2016160882A1 (en) | Methods for diagnosing and treating colorectal cancer using mirna549a | |
| CN111621573A (en) | Gastric cancer differentiation related marker miRNA composition and chip and application thereof | |
| CN109943561A (en) | A kind of primer, kit and its application | |
| CN108384855A (en) | Non-coding RNA and its application in bone and flesh tumor metastasis detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |